Teschner Sven, Stippel Dirk, Grunenberg Roland, Beck Bodo, Wahba Roger, Gathof Birgit, Benzing Thomas, Burst Volker
Transplant Center Cologne, University Hospital Cologne, Cologne, Germany.
J Clin Apher. 2012;27(2):51-60. doi: 10.1002/jca.21201. Epub 2012 Jan 23.
ABO-incompatible (ABOi) kidney transplantation is an established procedure relying on the removal of donor-specific isoagglutinine antibodies as part of the recipient preconditioning. At present, current protocols using immunoadsorption apply a single-use selective carbohydrate isoagglutinine adsorber. A regenerative and selective immunoglobulin immunoadsorption could be an alternative but has not been reported for ABOi transplantation.
Eight patients were treated with the commonly used isoagglutinine carbohydrate epitope adsorber and seven with a regenerative polyclonal sheep anti-immunoglobulin adsorber as part of the preconditioning for ABOi kidney transplantation. An IgG-isoagglutinine titer of less or equal 1:4 qualified for transplantation. Treatment safety, efficiency, length of desensitization, number of postoperative immunoadsorptions, and allograft outcome were retrospectively compared.
With the use of the immunoglobulin adsorber the median initial isoagglutinine IgG titers of 1:64 (range 1:32-1:256) were lowered to the target of 1:4 preoperatively with a mean of 6.2 immunoadsorptions (range 5-11). Mean IgG/IgM titer step reduction per IA was 1.98/1.21 for (range 0-4/0-4) and mean titer step rebound 1.31/0.82 (range 0-4/0-3), respectively. The number of immunoadsorptions and length of desensitization was not different from the use of the specific isoagglutinine adsorbers. After transplantation, no rejection occurred and only one postoperative immunoadsorption was necessary. No adverse events in relation to immunoadsorption were observed. Graft function was comparable to the isoagglutinine adsorber group.
These data suggest that ABOi kidney transplantation can be performed safely and effectively with a selective regenerative immunoglobulin immunoadsorber.
ABO血型不相容(ABOi)肾移植是一种成熟的手术,作为受体预处理的一部分,需要去除供体特异性同种凝集素抗体。目前,使用免疫吸附的现行方案采用一次性选择性碳水化合物同种凝集素吸附剂。可再生且选择性的免疫球蛋白免疫吸附可能是一种替代方法,但尚未见用于ABOi移植的报道。
8例患者在ABOi肾移植预处理过程中使用常用的同种凝集素碳水化合物表位吸附剂进行治疗,7例使用可再生的多克隆羊抗免疫球蛋白吸附剂进行治疗。IgG同种凝集素滴度小于或等于1:4符合移植条件。对治疗安全性、有效性、脱敏时间、术后免疫吸附次数及移植肾结局进行回顾性比较。
使用免疫球蛋白吸附剂时,术前初始同种凝集素IgG滴度中位数为1:64(范围1:32 - 1:256),降至目标值1:4,平均免疫吸附6.2次(范围5 - 11次)。每次免疫吸附时IgG/IgM滴度平均下降分别为1.98/1.21(范围0 - 4/0 - 4),滴度平均反弹分别为1.31/0.82(范围0 - 4/0 - 3)。免疫吸附次数和脱敏时间与使用特异性同种凝集素吸附剂无差异。移植后未发生排斥反应,仅需进行1次术后免疫吸附。未观察到与免疫吸附相关的不良事件。移植肾功能与同种凝集素吸附剂组相当。
这些数据表明,使用选择性可再生免疫球蛋白免疫吸附剂可安全有效地进行ABOi肾移植。